Evolus Expands Leadership Team with Appointments of Key Executives
October 22 2018 - 4:01PM
Appoints Kurt Knab as Vice President, Sales
Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic
medicine, today announced the expansion of its leadership team with
the appointments of three key executives reporting to David
Moatazedi, President and Chief Executive Officer. Evolus has
appointed Kurt Knab as Vice President of Sales, Alejandro “Alex”
Sabad as Vice President of Operations and Amy Marinne Fox as Vice
President of Human Resources. Each new executive has a proven track
record of excellence in their respective fields of expertise and
adds decades of experience to the Evolus leadership team.
David Moatazedi commented, “Evolus
continues to attract accomplished talent in the industry, and
we are pleased to announce the addition of these seasoned leaders
to our team. Their exceptional
backgrounds and industry knowledge complete our
leadership team as we rapidly advance towards anticipated FDA
approval in February 2019 and expected commercial launch in Spring
2019.”
Mr. Knab joins Evolus from Medline Industries
where he served as Vice President of Business Development and
Sales. Prior to that, Kurt spent sixteen years at LifeCell
Corporation where he held various roles in sales leadership and
ultimately served as Vice President, U.S. Sales for 4 years.
At LifeCell he was responsible for leading the commercial efforts
of the LifeCell’s entire portfolio including Alloderm®, Strattice®,
and Revolve®. Mr. Knab has over 20 years of commercial and
executive experience with top performing medical device
companies. He spent the early part of his career with Pfizer
and Mitek Products, an Ethicon Company, developing high growth
markets. Kurt earned a BS in Marketing from Penn State
University.
Mr. Sabad brings over 25 years of combined
industry & consulting experience with a range of life science
companies and is recognized for his expertise in global
manufacturing and operations. Mr. Sabad formerly served as a
Managing Director at Deloitte Consulting where he served as the
Technical Operations Solution and Global Manufacturing Strategy
& Operations Lead and led the Contract Development and
Manufacturing Organizations (CDMO) segment for the practice. Prior
to Deloitte, he served as Vice President of Operations Strategy and
Network Performance Management at MedImmune, AstraZeneca’s global
biologics division which contributed over $1.0 billion of annual
revenue. Mr. Sabad received an MBA in Strategy & Finance from
the Mendoza School of Business at the University of Notre Dame and
a BA from the University of California, Los Angeles.
Ms. Fox has over 20 years of experience building
high performing, agile organizations. Ms. Fox previously served as
Vice President, Human Resources of Orexigen Therapeutics, where she
led the design of employee retention programs and global HR
capabilities to meet organizational demands with system
implementations, metrics and process improvements. Prior to
Orexigen, she served as Director of Human Resources at Synteract, a
global Clincal Research Organization specializing in the delivery
of clinical trial solutions across multiple therapeutic areas.
Previously, she served as a Human Resources Manager at
Robbins Arroyo, a boutique law firm specializing in securities
litigation. Ms. Fox earned a BA in Literature-Writing at the
University of California San Diego. About
Evolus, Inc.
Evolus is a company dedicated to aesthetic
medicine focused on providing physicians and their patients with
expanded choices in aesthetic treatments and procedures. Evolus’
lead candidate DWP-450, also known by the chemical name
prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A
complex that was approved by Health Canada for the
temporary improvement in the appearance of moderate to severe
glabellar lines in adult patients under 65 years of age and is
being evaluated for marketing approval in the United
States and other areas.
Forward-Looking Statements
Statements made in this press release that
relate to future plans, events, prospects or performance are
forward-looking statements as defined under the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words “planned,” “expect,” “believes,” “strategy,” “opportunity,”
“anticipates,” “outlook,” “designed,” and similar words.
While these forward-looking statements are based on the current
expectations and beliefs of management, such forward-looking
statements are subject to a number of risks, uncertainties,
assumptions and other factors that could cause actual results to
differ materially from the expectations expressed in this press
release, including the risks and uncertainties disclosed in Evolus’
periodic filings with the Securities and Exchange Commission,
including factors described in the section entitled “Risk Factors”
in its Annual Report on Form 10-K for the year ended December 31,
2017 and its Quarterly Report on Form 10-Q for the Quarter ended
June 30, 2018, as filed with the Securities and Exchange Commission
on March 29, 2018 and August 2, 2018, respectively, all of which
are available online at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Except as required by law, Evolus
undertakes no obligation to update or revise any forward-looking
statements to reflect new information, changed circumstances or
unanticipated events.
Investors:Ashwin Agarwal, EvolusTel:
+1-949-284-4559Email: IR@Evolus.com
Brian Johnston, The Ruth GroupTel: +1
646-536-7028Email: IR@Evolus.com
General Media:Kirsten Thomas, The Ruth
GroupTel: +1-508-280-6592Email: kthomas@theruthgroup.com
Trade Media:Dani Shaffer, Alison Brod Marketing
+ CommunicationsTel: +1-212-230-1800Email:
evolus@alisonbrodmc.com
Alloderm®, Strattice®, and Revolve® are registered trademarks of
LifeCell Corporation.
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024